menu search

galectin therapeutics to share five scientific presentations at the liver meeting™ 2023, hosted by the aasld

Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of belapectin on cardiac repolarization (QT interval) ...

November 3, 2023, 12:00 pm

galectin therapeutics to participate in the h.c. wainwright 7th annual nash investor conference on october 24, 2023

NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

October 23, 2023, 8:00 am

galectin therapeutics to present update on its belapectin liver cirrhosis program at the 20th edition of discovery on target meeting, in boston, september 25-28, 2023

NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics, Inc.  (NASDAQ: GALT), the lea...

September 26, 2023, 8:00 am

galectin therapeutics to participate in the h.c. wainwright 25th annual global investment conference on september 13, 2023

NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leadin...

September 13, 2023, 5:22 pm

galectin therapeutics to participate in the h.c. wainwright 25th annual global investment conference on september 13, 2023

NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leadin...

September 11, 2023, 8:00 am

galectin therapeutics to present data on liver cirrhosis at the 9th edition of the paris nash meeting, at institut pasteur, september 7th & 8th 2023

NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leadin...

September 7, 2023, 12:00 pm

Galecto to present at investor conferences in september

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in ...

August 31, 2023, 11:00 am

What makes galectin therapeutics inc. (galt) a new buy stock

galectin Therapeutics Inc. (GALT) might move higher on growing optimism about its earnings prospects, w...

August 17, 2023, 1:17 pm

Galecto announces topline results from phase 2b galactic-1 trial of gb0139 for the treatment of idiopathic pulmonary fibrosis

Announces next steps for clinical development plan in severe liver diseases BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a...

August 15, 2023, 11:30 am

Galecto reports first quarter operating and financial results

BOSTON, April 28, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in ...

April 28, 2023, 12:00 pm

Bioxytran's positive phase 2 trial results featured in ‘vaccines' peer-reviewed journal

Bioxytran said positive top-line safety and efficacy results from the company's randomized, placebo-controlled Phase 2 clinical trial of its drug can...

March 29, 2023, 4:04 pm

galectin therapeutics to present at 6th obesity & nash drug development summit

NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

November 28, 2022, 8:00 am

galectin: ability to potentially target unmet medical need

Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in ...

July 11, 2022, 4:16 pm

Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

October 5, 2021, 3:39 pm

Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

October 5, 2021, 3:39 pm

Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

October 5, 2021, 3:39 pm

Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

October 5, 2021, 3:39 pm

Update: galectin therapeutics to participate in the h.c. wainwright 5th annual nash investor conference on october 12, 2021

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

October 5, 2021, 3:39 pm

galectin therapeutics to participate in the h.c. wainwright 23rd annual global investment conference

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

October 5, 2021, 1:55 pm

galectin therapeutics to participate in the h.c. wainwright 23rd annual global investment conference

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- galectin Therapeutics Inc. (NASDAQ: GALT), the leading...

October 5, 2021, 1:55 pm


Search within

Pages Search Results: